FDA Cracks Down on Websites Illegally Selling Opioids
The unapproved and misbranded opioids, which include tramadol and oxycodone, are being sold without a prescription.
Addiction/dependence
About Half of Waivered Clinicians Prescribe Buprenorphine for OUD
Percentages much higher for actively prescribing U.S. clinicians with 275 and 100 versus 30 patients
MPR Weekly Dose Podcast Episode 48
Treatment shows promise for patients who had pneumonia associated with COVID-19; A COVID-19 test that may have given inaccurate results; Neck gaiters as face masks may actually spread the virus; Drug applications are halted by the FDA; And Narcan has it’s shelf life extended. Also, we recap drug pipeline news from the past week.
Cannabidiol Studied as Potential Treatment for Cannabis Use Disorder
Abstinence from cannabis increased with cannabidiol 400mg, 800mg doses compared with placebo.
FDA Requires Labeling Changes for Opioids to Include Information About Naloxone
The FDA has announced that it is requiring drug manufacturers for all opioid pain relievers and medicines to treat opioid use disorder to include new recommendations about naloxone to the prescribing information.
USPSTF Urges Primary Care Docs to Ask Adults About Drug Use
Evidence inadequate to assess benefits and harms of screening for unhealthy drug use in teens.
Unapproved Cannabidiol, Curcumin Injectables Marketed for Multiple Disorders Recalled
Biota Biosciences announced the voluntary recall of CBD Complex, Curcumin Complex, and Cannabidiol + Curcumin Injectables due to the products being marketed without the approval of the FDA.
Aristada, Vivitrol Access Expanded During COVID-19 Pandemic
Alkermes has decided to expand the number of retail pharmacies and clinics where patients can receive access to Aristada (aripiprazole lauroxil) and Vivitrol (naltrexone extended-release injectable suspension).
E-Cigarette and Vaping-Associated Lung Injuries May Have Been Overlooked in the Past
Cases of e-cigarette or vaping product use–associated lung injury (EVALI) appear to have been overlooked in the past.
Physicians Report Low Interest in Opioid Use Disorder Meds
Few PCPs report obtaining buprenorphine waiver orprescribing buprenorphine, naltrexone for OUD.
